Clinical Trial Update: PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A [Phase 4]

View source ↗

Summary

Phase 4 clinical trial has completed and posted results for PF-05208756, moroctocog alfa (AF-CC), and Xyntha in Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Moroctocog alfa AF-CC (moroctocog alfa)
• PF-05208756
• Xyntha (recombinant coagulation factor VIII)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A | Phase 4 | Status: COMPLETED | Results posted: 2017-04-04